Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EIF3C
REST API REST API
Homo sapiens
EIF3C is differentially expressed in 268 experiments: 110 organism parts: prostate, testis, ... (108 more);, 152 disease states: normal, Huntington's disease, ... (150 more);, 79 cell types 346 cell lines 32 compound treatments and 71 other conditions.
Synonyms EIF3S8, eIF3-p110, eIF3c
Orthologs Eif3c (Mus musculus)   EIF3C_BOVIN (Bos taurus)   Eif3c (Rattus norvegicus)   eif3c (Danio rerio)   NIP1 (Saccharomyces cerevisiae)   eIF3-S8 (Drosophila melanogaster)   eif3c (Xenopus laevis)   ENSCAFG00000017143 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoplasm, eukaryotic translation initiation factor 3 complex, cellular protein metabolic process, translation, translational initiation, translation initiation factor activity, gene expression
InterPro Term PCI_dom, eIF3c_N
UniProt Accession Q99613, C9JJ55, B4DVQ5, B4DVU3, B4DRU0, B3KNZ4, F5H1I1
Search EB-eye ENSG00000184110
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (35 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HT1080
2
E-MTAB-37, E-GEOD-20089
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF7
2
E-GEOD-5258, E-MTAB-37
340 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-20677, ... (41 experiments)

Factor Value U/D Experiments
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD4+ T cell
7
2
E-GEOD-16190, E-MTAB-24
SVGR2
1
E-GEOD-7819
n/a
1
E-MTAB-24
CD33+ myeloid
2
1
E-AFMX-5
hematopoietic stem cell
1
E-MEXP-1403
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-5370, E-MTAB-62, ... (51 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-MTAB-62, E-GEOD-6014, E-MTAB-37
breast carcinoma
2
E-MTAB-37, E-TABM-276
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
control
2
E-GEOD-21912, E-GEOD-8121
lung adenocarcinoma
2
E-MTAB-37, E-GEOD-2514
146 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-15205, E-GEOD-3720, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
none
2
8
E-GEOD-5824, E-MEXP-1601, E-MEXP-1958, E-GEOD-2649, E-GEOD-412, ... (10 experiments)
TNF
1
E-GEOD-15205
heregulin
1
E-GEOD-6462
Cxcl12
1
E-GEOD-7307
4OH-tamoxifen
1
E-GEOD-2292
17beta-estradiol
4
1
E-GEOD-2292
26 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd38
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-MEXP-1251, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7578, E-MTAB-108, E-MEXP-2340, E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-1045, E-GEOD-2466, E-GEOD-22593, E-TABM-868, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-20540, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (42 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-7179

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-21750, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.428 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM